It has become customary that a session is held at the British Association of Urological Surgeons (BAUS) annual meeting wherein the most important advances in the major urological sub-specialities are summarised by British opinion leaders for the benefit of the core urologist. It gives us pleasure to present in this paper (to which the six authors contributed equally) the topics covered at the Liverpool BAUS meeting in June 2016.
AhmedHUBosailyAEBrownLCThe PROMIS study: a paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. J Clin Oncol2016; 34(Suppl): 5000.
2.
SathianathenNJMurphyDGvan den BurghRCGleason pattern 4: active surveillance no more. BJU Int2016; 117: 856–857.
3.
JamesNDSydesMRClarkeNWAddition of docetaxel, zolendronic acid or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive multiarm multistage platform randomised controlled trial. Lancet2016; 387: 1163–1177.
4.
Cancer Research UK. Bladder cancer statistics, www.cancerresearchuk.org (2014, accessed June 2016).
5.
MoralesEEGrillSSvatekRSFinasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol2016; 69: 407–410.
6.
NaitoSAlgabaFBabjukMThe Clinical Research office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging assisted TURBT in primary non-muscle invasive bladder cancer patients: trial protocol and one-year results. Eur Urol. Epub ahead of print 3May2016. DOI: 10.1016/j.eururo.2016.03.053.
7.
RinkMBabjukMCattoJHexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol2013; 64: 624–638.
8.
BabjukMBohleABurgerMEAU guidelines on non-muscle invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. Epub ahead of print 17June2016. DOI: 10.1016/j.eururo.2016.05.041.
9.
GonteroPSylvesterRPisanoFThe impact of re-transurethral resection on clinical outcomes in a large multicenter cohort of patients with T1 high grade/Grade 3 bladder cancer treated with bacilli Calmette-Guerin. BJU Int2016; 118: 44–52.
10.
MostafidHM.Time to re-evaluate and refine re-transurethral resection in bladder cancer?BJU Int2016; 118: 9–10.
11.
GanCAmerySChattertonKSequential bacillus Calmette–Guerin/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2 year outcomes. J Urol2016; 195: 1697–1703.
12.
ArendsTNativOMaffezziniMResults of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette–Guerin for adjuvant treatment of patients with intermediate and high risk non-muscle invasive bladder cancer. Eur Urol2016; 69: 1046–1052.
13.
JeffriesERCresswellJMcGrathJOpen radical cystectomy in the UK – the current standard of care? Analysis of the BAUS cystectomy audit. Annual meeting of the British Association of Urologists, Liverpool, June 27th–30th 2016. J Clin Urol2016; 9: 11.
14.
MillerCCresswellJRoweEThe BAUS radical cystectomy audit – an update on current clinical practice (2014), and an analysis of differences in practice between centres and surgeons performing differing volumes of surgery. Annual meeting of the British Association of Urologists, Liverpool, June 27th–30th 2016. J Clin Urol2016; 9: 22.
15.
KoupparisAVilleda SandovalCGillattDRobot-assisted radical cystectomy with intracorporeal urinary diversion: impact on an established enhanced recovery protocol. BJU Int2015; 116: 924–931.
16.
KhanMSGanCAhmedKA single-centre early phase randomised controlled three-arm trial of open, robotic and laparoscopic radical cystectomy (CORAL). Eur Urol2016; 69: 613–621.
17.
PietzakEJChaEZaborEProgression from non-muscle invasive bladder cancer (NMIBC) to muscle invasion is associated with lower response rates to neoadjuvant chemotherapy. Annual meeting of the American Urological Association, San Diego, 6th–10th May 2016. J Urol2016; 195: e408–e409.
18.
PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature2014; 515: 558–562.
19.
FernandoAFowlerSO’BrienTon behalf of British Association of Urological Surgeons (BAUS). Nephron-sparing surgery across a nation – outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit. BJU Int2016; 117: 874–882.
20.
LinehanWMSpellmanPTRickettsCJComprehensive molecular characterization of papillary renal-cell carcinoma: cancer genome atlas research network. N Engl J Med2016; 374: 135–145.
21.
HaasNBManolaJUzzoRGLocally advanced kidney cancer in the randomized, placebo-controlled, multicenter, phase III Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE) trial. Lancet2016; 387: 2008–2016.
22.
ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol2016; 17: 917–927.
23.
MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373: 1803–1813.
24.
BisslerJJKingswoodJCRadzikowskaEverolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant2016; 31: 111–119.
25.
GratzkeCBachmannADescazeaudAEAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol2015; 67: 1099–1109.
26.
ThomasJATubaroABarberNA multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH Study. Eur Urol2016; 69: 94–102.
27.
National Institute for Health and Care Excellence (NICE). GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technology guidance (MTG29). London: NICE, 2016.
28.
JonesPRajkumarGNRaiBPMedium term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. Urology. Epub ahead of print 18May2016. DOI: 10.1016/j.urology.2016.05.003.
29.
PereraMRobertsMJDoiSAProstatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol2015; 67: 704–713.
30.
RayAMorganHWilkesAThe Urolift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a NICE medical technology guidance. Appl Health Econ Health Policy. Epub ahead of print 30Jan2016. DOI: ?.
31.
National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technology guidance (MTG26). London: NICE, 2015.
32.
RoehrbornCGRukstalisDBBarkinJThree year results of the prostatic urethral L.I.F.T study. Can J Urol2015; 22: 7772–7782.
33.
RoehrbornCGangeSShoreNPD21–02 Prospective, randomized, blinded study of Prostatic Urethral Lift (PUL): four year results. J Urol2016; 195(4S Suppl): e456.
34.
SønksenJBarberNSpeakmanM2016. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12 month results from the BPH6 Study. Eur Urol2015; 68: 643–652.
35.
GillingPReutherRKahokehrAAquablation – image guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int2016; 117: 923–929.
36.
BaileyKAbramsPBlairPSUrodynamics for Prostate Surgery Trial: Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men: study protocol for a randomised controlled trial. Trials2015; 16: 567.
37.
DrakeMJChappleCEsenAAEfficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol2016; 70: 136–145.
38.
National Institute for Health Research. HTA – 13/88/21: ALternative To prophylactic Antibiotics for the treatment of Recurrent urinary tract infections in women (ALTAR study), www.nets.nihr.ac.uk/projects/hta/138821 (2016, accessed 12 June 2016).
39.
CashmanSThiruchelvamNMorleyR.Results of the British Association of Urological Surgeons female stress urinary incontinence procedures outcome audit. JCU2016; 9(IS): 9.
40.
StephensonRCarnellSJohnsonNOpen urethroplasty versus endoscopic urethrotomy – clarifying the management of men with recurrent urethral stricture (the OPEN trial): study protocol for a randomised controlled trial. Trials2015; 16: 600.
SilvaLAAndrioloRBAtallahANSurgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. Cochrane Database Syst Rev2014; 9: CD008306.
43.
National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: assessment and management. London: NICE, 2015.
HeersHTurneyBW.Trends in urological stone disease: a 5-year update of hospital episode statistics. BJU Int. Epub ahead of print 1May2016. DOI: 10.1111/bju.13520.
51.
FurykJSChuKBanksCDistal ureteric stones and tamsulosin: a double-blind, placebo-controlled, randomized, multicenter trial. Ann Emerg Med2016; 67: 86–95
52.
PickardRStarrKMacLennanGMedical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet2015; 386: 341–349.
53.
SomaniBKAl-QahtaniSMde MedinaSDOutcomes of flexible ureterorenoscopy and laser fragmentation for renal stones: comparison between digital and conventional ureteroscope. Urology2013; 82: 1017–1019.
54.
SkolarikosAGrossAJKrebsAOutcomes of flexible ureterorenoscopy for solitary renal stones in the CROES URS Global Study. J Urol. 2015; 194: 137–143.
55.
FinchWJohnstonRShaidaNMeasuring stone volume – three-dimensional software reconstruction or an ellipsoid algebra formula?BJU Int2014; 113: 610–614.
56.
KronenbergPTraxerO.In vitro fragmentation efficiency of holmium: yttrium-aluminum-garnet (YAG) laser lithotripsy: a comprehensive study encompassing different frequencies, pulse energies, total power levels and laser fibre diameters. BJU Int2014; 114: 261–267.
57.
KuntzNJNeisiusATsivianMBalloon dilation of the ureter: a contemporary review of outcomes and complications. J Urol2015; 194: 413–417.
58.
OliverRWellsHTraxerOUreteric stents on extraction strings: a systematic review of literature. Urolithiasis. Epub ahead of print 20Jun2016. DOI: ?.
59.
ZhuWLiuYLiuLMinimally invasive versus standard percutaneous nephrolithotomy: a meta-analysis. Urolithiasis2015; 43: 563–570.
60.
DeSAutorinoRKimFJPercutaneous nephrolithotomy versus retrograde intrarenal surgery: a systematic review and meta-analysis. Eur Urol2015; 67: 125–137.
61.
OsmanYHarrazAMEl-NahasARClinically insignificant residual fragments: an acceptable term in the computed tomography era?Urology2013; 81: 723–726.
62.
CandauCSaussineCLangHNatural history of residual renal stone fragments after ESWL. Eur Urol2000; 37: 18–22.
63.
SahinCKafkasliACetinelCAHow do the residual fragments after SWL affect the health-related quality of life? A critical analysis in a size-based manner. Urolithiasis2015; 43: 163–170.
64.
ChewBHBrotherhoodHLSurRLNatural History, complications and re-intervention rates of asymptomatic residual stone fragments after ureteroscopy: a report from the EDGE Research Consortium. J Urol. 2016; 195(4P1): 982–986.
